Gates foundation grant to combat malaria drug resistance
Posted Jun 15 2009 6:27pm
London (PTI): An international network of malaria scientists is to be established to map the emergence of resistance to anti-malarial drugs and guide global efforts to control and eradicate the disease, thanks to a £12.5 million grant from the Bill and Melinda Gates Foundation.
The Worldwide Antimalarial Resistance Network ( WWARN ) will provide the comprehensive and rigorous evidence base needed for policy makers to select the best anti-malarial treatments and to formulate strategies to control the critical problem of resistance wherever it arises.
“With this critical mass of data, we will have powerful evidence to help inform decisions by policy makers,” says Dr. Philippe Guerin, Director of WWARN and an epidemiologist in the Centre for Tropical Medicine at the University of Oxford.
“It is crucial that we provide all patients with access to the right drugs at the right time.”
Malaria is preventable and treatable, yet a million people die from malaria each year, most of them children.
About 2.5 billion people, or 40 per cent of the world’s population, are at risk of the disease.
These people mainly live in the poorest countries of the world, those least able to provide effective controls against the disease.
Prevention of infection is one important facet of malaria control, but with no vaccine against malaria, treatment relies on anti-malarial drugs. The World Health Organisation(WHO ) has declared that the emergence of resistance to these drugs is a crucial problem, which could seriously undermine efforts to control the disease.
WWARN will integrate the efforts of researchers, NGOs and public health expert s in malaria-endemic areas around the world.
Four years in planning, the initiative was born in the scientific community as malaria scientists became aware that broad collaboration was critical to achieving the long-term goal of eliminating the disease. The international collaborative effort will be administered and supported from Oxford University.
WWARN will work in close collaboration with WHO to enhance anti-malarial resistance surveillance. The tie-up will provide a platform for all malaria scientists to share results, improving the coverage, quality, and timeliness of the available data. This will give an up-to-the-minute picture of the effectiveness of anti-malarial drugs at national, regional and global levels, and enable policy makers to respond more quickly to early signs of resistance.
“We need to gather the very best intelligence to alert the malaria community to signs of resistance and mobilise our best weapons on the frontline,” says Professor Carol Sibley, Scientific Director of WWARN.
While the Plasmodium parasite that causes malaria has been resistant to older drugs such as chloroquine and sulphadoxine-pyrimethamine for some time, evidence emerging from Cambodia suggests the parasite is even developing a tolerance to artemisinin.
This recently developed drug, made from a Chinese herb, is the best line of defence against malaria and it is critical that we contain any resistance to artemisinin.
“We need readily accessible, quality assured and up-to-date information on anti-malarial drug resistance if we are to eliminate malaria. WWARN will provide this essential intelligence,” says Nick J. White, Professor of Tropical Medicine at Mahidol University in Thailand and Oxford University, and Chair of the Board of WWARN.
Current guidelines stipulate that artemisinin should be given in combination with other anti-malarials to protect as much possible against the development of drug resistance.
However, this advice is being undermined by the lack of access to artemisinin combination therapies, their cost and the prevalence of poor quality drugs in many parts of the world. One recent study from South East Asia found that 195 anti-malarial drug samples out of 391 were fake.
“This situation is the best way to ensure the malaria parasite rapidly develops resistance to our best treatments,” Poor quality or fake drugs expose the malaria parasite to smaller amounts of the drug which gives the parasite the opportunity to evolve ways to evade the drug,” says Dr. Guerin.